your market intelligence analyst
Search Results
16 results
Your search is now limited to «Celgene» expert search.
Human medicines European public assessment report (EPAR): Thalidomide Celgene (previously Thalidomide Pharmion), thalidomide, Multiple Myeloma, Date of authorisation: 16/04/2008, Revision: 24, Status: Authorised.
Investing News Network 08/16/2019 12:35
Celgene (NASDAQ:CELG) has announced that the US Food and Drug Administration (FDA) has approved INREBIC to treat adult patients with myelofibrosis. As quoted in the press release: “The approval of INREBIC is another important milestone for Celgene and underscores our commitment to people living with blood cancers,” said Jay Backstrom, M.D., M.P.H., Chief Medical Officer …. .

Financial Services

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Political Entities


Strategic Scenarios



  • Actions
    • Bookmark and Share: Allows you to Bookmark the page for easy future retrieval and sharing with colleagues
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • Previous Versions: Only shown if essentially the same document has been republished
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Save" button to the right of the search box. 

Click here for more info on Search Results.